November 2016 Br J Cardiol 2016;23:132
David Mantle
I wish to comment on recent work linking non-alcholic fatty liver disease (NAFLD) with a high risk of cardiovascular mortality.1,2 One issue which has not been addressed in these studies is the potential role of coenzyme Q10 (CoQ10) deficiency in the pathogenesis both of NAFLD and subsequent cardiovascular disease. CoQ10 is a vitamin-like substance that plays a key role in the biochemical process supplying all cells with energy. CoQ10 also has antioxidant and anti-inflammatory action. An adequate supply of CoQ10 is particularly important in tissues with a high energy requirement, such as the heart and liver. Most of the body’s daily req
June 2015 Br J Cardiol 2015;22:68
Dr David Mantle
Dear Sirs, We wish to comment on two recent clinical trial studies relating to the use of supplementary coenzyme Q10 (CoQ10) for the treatment and prevention of cardiovascular disease. In the first randomised controlled trial, the Q-Symbio study by Mortensen et al,1 oral supplementation with CoQ10 (300 mg/day for two years, as an adjuvant to conventional medication) in 420 patients with chronic heart failure (New York Heart Association class III or IV) reduced the risk of cardiac related mortality by 47% compared to placebo. In the second randomised controlled trial, the KiSel-10 study by Alehagen et al,2 oral supplementation with CoQ10 (200
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits